

The Clinical Profile of the Woman at Increased Risk of Placenta Accreta Spectrum Disorders: Proposal of a Practical Screening Guideline

O Perfil Clínico da Mulher com Risco Acrescido de Acretismo Placentar: Proposta de uma *Guideline* de Rastreio

Anáisa S. Simões¹, Francisco Caramelo², Isabel Santos Silva³
Faculdade de Medicina da Universidade de Coimbra

Abstract

Placenta Accreta Spectrum (PAS) disorders, though uncommon, are a leading cause of maternal morbimortality in modern obstetrics. They can lead to life-threatening complications, such as massive obstetric hemorrhage and hemorrhagic shock, often needing a peripartum hysterectomy. Prenatal diagnosis is crucial for optimal management and outcomes. Still, recent studies show that most cases remain undiagnosed until delivery. Studies suggest that a systematic screening process incorporating prenatal imaging and risk factors can enhance predictive accuracy. This systematic review focuses on better understanding the clinical risk factors that increase the risk for these disorders, thus answering the clinical need for targeted prenatal screening.

Keywords: Placenta Accreta Spectrum; Abnormal placentation; Prenatal diagnosis; Early screening; Clinical risk factors.

Resumo

O Acretismo Placentar (AP), embora incomum, é uma das principais causas de morbimortalidade materna na obstetrícia moderna. É potencialmente fatal, podendo complicar-se com hemorragia obstétrica maciça e choque hemorrágico, frequentemente motivando uma histerectomia periparto. O diagnóstico pré-natal é crucial para otimizar a sua abordagem. Ainda assim, estudos recentes mostram que a maioria dos casos não é diagnosticada até ao parto e que um rastreio sistemático combinando a imagiologia com o perfil clínico da mulher pode aumentar a precisão preditiva diagnóstica. Esta revisão sistemática focou-se na melhor compreensão destes fatores de risco, respondendo à necessidade clínica de uma triagem pré-natal dirigida.

Palavras-chave: Acretismo placentar; Anomalias da placentação; Diagnóstico pré-natal; Rastreio precoce; Fatores de risco clínicos.

BACKGROUND

Placenta Accreta Spectrum (PAS) is a relatively new umbrella term implemented in 2019 in the consensus guidelines developed by the International Federation of Gynecology and Obstetrics (FIGO), used for describing a complex disorder of placental deve-

lopment. There are three grades of PAS¹, that depend on the depth and severity of myometrial invasion: in **accreta**, rather than being restricted within the decidua basalis, the chorionic villi attach to the myometrium; in **increta**, the chorionic villi invade the myometrium; in **percreta**, this invasion goes through the perimetrium, to and beyond the uterine serosa.

The most consensual explanation regarding its etiology hypothesizes that a defect of the endometrial – myometrial interface leads to an abnormal decidualization in an area of scar tissue, which allows abnormally deep placental anchoring villi and trophoblastic infiltration^{1,2}.

Although still infrequent, PAS disorders are a growing concern and represent one of the most important causes of maternal morbimortality in modern obstetrics. They present a potentially life-threatening event, especially if not detected before delivery, as they affect the normal detachment of the placenta during the third stage of labor. Massive obstetric hemorrhage is one of its major complications, possibly leading to hemorrhagic shock and coagulopathy, often needing a peripartum hysterectomy to prevent maternal death. They can also be a cause of injury to the surrounding organs^{1,2}.

Understandably, it can additionally have a tremendous psychological impact, with increased risks of fertility loss, prolonged hospital admission, and overall morbidity³, which increase the risk of perinatal mental health disorders in a period of increased vulnerability to these conditions.

Prenatal diagnosis is key because it provides an opportunity to optimize management and outcomes. In PAS, maternal morbimortality is significantly reduced when the delivery is planned and occurs in a specialized center, under the care of a multidisciplinary team⁴. This approach is associated with shorter operative time, decreased maternal hemorrhagic morbidity, and fewer intensive care unit admissions, as well as better neonatal outcomes^{5,6}.

The referral of suspected cases has been suggested as one of the most important measures in determining both maternal and neonatal outcomes⁷, thus implying that it is possible to optimize outcomes, even among women with a clinical high-risk profile. This referral, however, hinges on the identification of susceptible women and on precise prenatal assessment.

Still, recent population studies have shown that PAS disorders remain undiagnosed until delivery from half to two-thirds of the cases², and are usually identified during labor when the placenta is retained, and/or there is heavy hemorrhage while attempting to remove it manually⁸.

Its contemporary global trend highlights the clinical need for an effective systematic screening guideline for this disorder in referring healthcare settings. Recently, studies have shown the combination of prenatal imaging with maternal and pregnancy risk factors improves the predictive accuracy of both the presence and severity of PAS⁹⁻¹³.

The major clinical factors that increase the risk of developing PAS are widely recognized, and most cases are associated with placenta previa (PP) and a history of cesarean section (CS) delivery. Other risk factors have also been identified, such as maternal age, multiparity, uterine interventions, and assisted reproductive techniques (ART)¹.

Ultimately, it seems evident that a more comprehensive understanding of the clinical profile of women at a higher risk of developing PAS disorders would represent a significant development in guiding targeted prenatal screening efforts and increasing the rate of antenatal diagnosis.

OBJECTIVES

To perform a systematic review and meta-analysis of the possible major clinical risk factors for PAS and estimate their risk. The primary goal is to establish the clinical profile of the woman at increased risk, combining the clinical risk factors associated with PAS into a practical screening guideline.

METHODS

Study design

This systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and flowchart. The study protocol was registered in PROSPERO with the registration ID CRD42023360340.

1. Faculty of Medicine, University of Coimbra, Portugal.
2. Doctorate, Assistant Professor at Faculty of Medicine, University of Coimbra, Portugal.
3. Medical Doctor at Department of Obstetrics B, in Maternidade Bissaya Barreto, Centro Hospitalar e Universitário da Universidade de Coimbra, Portugal.

The research question was defined using PICO principles: the population was the general obstetric population; the interventions/exposures were the following maternal clinical risk factors: number of previous cesarian deliveries, presence of placenta previa, maternal age, parity, maternal body mass index (BMI), previous uterine intervention, ART, hypertensive disorders and history of smoking during pregnancy; the comparator was the absence of the previously named risk factors; the main outcome was the occurrence of PAS.

We included both the cases where a histopathologic confirmation was obtained – if a hysterectomy was performed –, and the clinically diagnosed cases of PAS – categorized into “clinical PAS” –, when a conservative approach was taken, which included at least one of the following: (1) the absence of placenta separation 30 minutes after vaginal delivery, despite active management in third-stage labor, including intravenous infusion of synthetic oxytocin, uterine massage, and controlled cord traction, (2) difficult manual or fragmentary removal of the placenta and heavy bleeding from the placentation site, with partial or no placental separation during delivery and (3) evidence of gross placental invasion intraoperatively.

Search Strategy

A literature search was performed in three databases – PubMed, EMBASE, and The Cochrane Library –, between June 2022 and December 2022, using the Medical Subjects Heading Terms (MeSH) and with the following search phrases – for PubMed: ((placenta increta) OR (placenta percreta) OR (placenta accreta) AND (risk factors)); for Embase and Cochrane CENTRAL: ((placenta accreta spectrum) AND (clinical risk factors)).

The PRISMA flow diagram for the identification of studies is presented in Figure 1.

Eligibility criteria

Studies that fulfilled the following inclusion criteria were included (1) articles focused on the clinical risk factors associated with PAS, confirmed clinically and/or histopathologically, in the general obstetric population, (2) studies that were published in 2019 and beyond, after FIGO’s Clinical Grading System was established, to

support the process of clarifying reported data on PAS in international literature, (3) studies limited to the English and Portuguese languages (4) studies limited to human subjects.

Data Extraction and Study Selection

The remaining articles were then independently screened for inclusion criteria by two reviewers (A.S and I.S.S), based on titles and abstracts. The reasons for excluding trials were recorded. Next, a screening of the full-text reports of the remaining articles was performed, after which it was decided whether those met the inclusion criteria.

The eligible articles were analyzed and information was extracted: *study characteristics* (first author, publication year, study design, country, sample size), *participant characteristics* (population demographics and risk factors), *measure used for the point estimates* (OR). Data were stored on Microsoft Excel spreadsheets.

With the extracted data, a meta-analysis was performed when possible. A random effects model was used, and the results were presented in forest plots. To assess heterogeneity between studies, Cochran’s Q test and the I² index were used. The analysis was performed in R using the package metafor, and a significance level of 0.05 was considered. Forest plots were produced in MS® Excel® from the R results.

Quality Assessment for the included studies was performed following adapted versions of assessment Scales by the American National Heart, Lung and Blood Institute (NHLBI).

RESULTS

A total of 36 studies were finally included in the systematic review, the majority of which were conducted in China and the USA, followed by Italy. In “maternal age”, “number of fetuses/multiple gestations” and “hypertension disorders”, we did not find sufficient data to perform a meta-analysis.

We found that PP (OR 34.69, 95% CI[9.41; 127.89]), a history of two or more previous CS (OR 5.84, 95%CI[2.69; 12.67]), ART (OR 4.19, 95%CI[3.06; 5.73]), uterine interventions (OR 3.41,




FIGURE 1. PRISMA flow diagram of the identification of screened and included studies.

95%CI[2.37; 4.92]), and multiparity (OR 3.22, 95%CI[1.26; 8.24]) were risk factors for the development of PAS disorders. Results regarding maternal BMI and smoking during pregnancy were not statistically significant.

A table of summarized results is presented in Table I.

DISCUSSION

Women with the **combination of placenta previa and at least one prior CS** have clearly and consistently been identified as a high-risk clinical profile for PAS^{1,14,15}. Our results support these findings, as these two risk factors had the biggest estimated OR. The

TABLE I. SUMMARIZED RESULTS FOR EACH RISK FACTOR IN THE INCLUDED STUDIES.

Risk factor	Estimated OR	Heterogeneity	Number of Studies	p Value
Placenta previa	34.69 (95% CI: [9.41; 127.89])	I ² =98.9%	25/36	p<0.001
≥2 Previous CS	5.84 (95% CI[2.69; 12.67])	I ² =98.3%	35/36	p<0.001
ART	4.19 (95% CI[3.06; 5.73])	I ² =70.5%	18/36	p<0.001
Uterine Interventions	3.41 (95% CI[2.37; 4.92])	I ² =0.0%	19/36	p<0.001
Multiparity	3.22 (95% CI[1.26; 8.24])	I ² =97.8%	18/36	p=0.014
Smoking	1.76 (95% CI[0.76; 4.09])	I ² =53.1%	7/36	p=0.190
Maternal BMI				
Overweight	1.40 (95% CI[0.86; 2.27])	I ² =94.8%	25/36	p=0.176
Obesity	0.99 (95% CI[0.89; 1.10])	I ² = 18.4%		p=1.000

work of Conturie and Lyell¹⁶ also found that women with both placenta previa and a history of cesarean delivery are more likely to have a higher grade of invasive PAS. Both conditions are identified as independent risk factors for PAS and their identification plays a critical role in both its diagnosis and optimal management.

Placenta previa emerged as the most significant finding in our study. Although it cannot be prevented, its early detection and meticulous management are crucial for achieving the best possible outcomes. These patients require close monitoring throughout their pregnancy and may need a planned cesarean delivery to prevent complications.

Our results also found that a history of **previous CS** was associated with a higher risk of developing PAS. While we did not study this, other studies have also consistently identified a cumulative association between a previous CS and PAS¹⁷, highlighting its importance and significance as a major clinical risk factor. This is a particularly important finding because a history of previous cesarean delivery is the potentially modifiable risk factor most strongly associated with these disorders.

It is important to acknowledge that other factors can also contribute to the development of PAS – it is impe-

orative that healthcare providers remain highly vigilant and consider PAS in women presenting with other known associated risk factors.

A recent meta-analysis showed that pregnancies after **ART** are associated with higher risks of both obstetric and perinatal complications when compared with spontaneous conception, including a significantly increased risk of abnormal placentation, especially for PAS and vasa previa¹⁹. Our results paralleled this and other recent studies, supporting the hypothesis that ART increases the risk of PAS.

Our results also supported previous studies that found that **uterine interventions** increased the risk of PAS¹⁵, as any procedure damaging to the integrity of the uterine lining can theoretically cause abnormal placentation²⁰.

Our results also suggest that **multiparity** is a significant risk factor for PAS. Multiple pregnancies can cause changes in the uterine environment, such as uterine scarring or damage to the endometrial lining. Additionally, with each pregnancy, the uterine wall becomes thinner, making it easier for the placenta to invade and grow deeply into the uterus²⁰.

When it comes to **smoking during pregnancy**, our results were not statistically significant. Nonetheless,

other studies have found that smoking during pregnancy may increase the risk of PAS^{12,21-23} because it (1) impairs wound healing of scarred uterus and has been linked to changes in the structure and function of the placenta, which may increase the risk of abnormal placentation and (2) also increases the risk of placenta previa²¹.

It is known that women with **advanced maternal age** are at a higher risk of various adverse maternal and neonatal outcomes. The work of Humaira Ali *et al.* showed that the odds of PAS increased for every one-year increase in age in women with a previous cesarean²⁴. Although these findings may be confounded by higher parity, placenta previa risk, and higher probability of a previous uterine intervention or fertility treatments, it may also represent an altered hormonal and/or implantation environment, as suggested by various studies where advanced maternal age was found to be an independent risk factor for PAS^{8,25,26}. As delayed child-bearing becomes increasingly more common, we argue that addressing maternal age and its possible association with PAS is important.

The occurrence of PAS has been recently reported to be higher in **multiple gestations**, possibly because there is excessive myometrium stretching and enlargement of the placenta^{9,27}, although current data on this topic is still scarce.

The data on the association of **hypertensive disorders** and PAS is mixed and scarce. Because the presence of PAS has been linked to increase the risk of adverse outcomes in women with hypertensive disorders²⁸, including severe bleeding and emergency hysterectomy, we recommend careful monitoring.

Regarding **maternal BMI**, it remains unclear whether its association with PAS is independent of confounding factors, such as the higher risk of cesarean delivery commonly observed in obese women. As high maternal BMI can increase the risk of other various complications for both the mother and the baby, including labor complications that can make the management of a concomitant PAS disorder even more challenging, we suggest close monitoring of these women.

It is important to note that not all cases of adherent placenta require major surgery, and conservative management can be successful in some cases²⁹. In patients with adherent placentas requiring manual extraction,

the pathologic finding of **focal accreta** is associated with an increased risk of hemorrhagic morbidity and retained placenta in subsequent pregnancies^{30,31}.

OUR GUIDELINE

We believe that the key measure in optimizing both prenatal diagnosis and outcomes of women at increased risk for PAS is the referral of suspected cases, which implies that healthcare providers should know whom to refer and when to do it – and, thus, profiling women by their clinical risk is crucial.

We aimed to combine our findings and current knowledge on the clinical risk factors associated with PAS into a prediction guideline, to provide recommendations on the best approaches to the screening of PAS.

Our guideline defines who should be screened, who is responsible for performing the screening, the tool to be used and what defines a positive screen test, as well as what should be done with a positive result.

We suggest that the standardized routine prenatal care visits and ultrasounds present an unmissable opportunity to also actively screen for PAS risk factors. Additionally, preventive measures can be taken (and will ideally start during preconception counselling), such as: promoting vaginal delivery, which includes encouraging women with a previous CS to attempt trial of labor for subsequent births, if clinically safe; counselling about nutrition and exercise and support smoking cessation; advising women considering undergoing ART; and addressing the role of maternal age on reproductive planning and outcomes.


All pregnant patients should be screened, and the screening process can be carried out by any healthcare professional, who should continue to search for risk factors and any alterations during every prenatal care visit and routine ultrasound. We propose starting by implementing the checklist suggested in Table II and acting according to its final score.

A score lower than 2 points defines a low-risk clinical profile. We suggest maintaining a screening program similar to any other pregnant woman.

A score between 2 and 5 points defines an intermediate-risk clinical profile – if placenta previa is

TABLE II. CLINICAL RISK FACTORS TO CONSIDER AND RESPECTIVE FINAL CLINICAL RISK PROFILE FOR PAS DISORDERS.

Risk factor	Action
Combination of history of 1 previous cesarian delivery + placenta previa in the current pregnancy ^a	Add 6 points
Any additional previous cesarian delivery	Add an extra 1 point
History of 1 previous cesarian section ^b	Add 2 points
Any additional previous cesarian delivery	Add an extra 1 point
Placenta previa in the current pregnancy ^c	Add 2 points
History of previous manual removal of the placenta	Add 1 point
Use of assisted reproductive techniques (ART)	Add 1 point
History of uterine intervention <ul style="list-style-type: none"> • previous uterine surgery • dilation and curettage • endometritis • hysteroscopic surgery • endometrial ablation 	Add 1 point
Multiparity	Add 1 point
Smoking during pregnancy	Add 1 point
Multiple gestation	Add 1 point
Advanced maternal age (>35 years)	
Hypertensive disorders	maintain active surveillance
Overweight or obese (maternal BMI >25 kg/m ²)	



Added Final Score and Respective Clinical Profile

- **Score of < 2 Points** → Low-risk clinical profile
- **Score of 2-5 Points** → Intermediate-risk clinical profile
- **Score of ≥ 6 Points** → High-risk clinical profile

^a the combination of a “history of 1 previous cesarian delivery PLUS a placenta previa diagnosis in the current pregnancy” should punctuate 6 points; any additional cesarian delivery should add an extra 1 point;

^b the history of 1 previous cesarian delivery, in the absence of a placenta previa diagnosis in the current pregnancy, should punctuate 2 points; any additional cesarian delivery should add an extra 1 point;

^c the diagnosis of a placenta previa in the current pregnancy, in the absence of a history of a previous cesarian delivery, should punctuate 2 points.

suspected or identified, we suggest women should undergo regular ultrasound examinations during the second and third trimesters to confirm persistent previa and consider referral.

A score of 6 points or more defines a high-risk clinical profile and we recommend immediate referral to a specialized diagnostic center, experienced in PAS disorders.

The main strengths of our work are that this triage of women: (1) can be carried out by any healthcare provider, in both a primary care setting and a medical facility with limited resources, (2) does not necessarily require additional medical appointments beyond those that are already scheduled for prenatal general care, (3) proposes a score that considers the different relative clinical importance of each risk factor, attributing

points according to its clinical significance and (4) as a screening test, it can identify potential health problems before they become life-threatening conditions, which in turn can reduce associated healthcare costs, thus improving preventive care and overall health equity by increasing early access to affordable healthcare services.

The main limitations are: (1) our guideline will need validation and (2) our meta-analysis was complicated by heterogeneous subsets of women and methodology across studies. High heterogeneity can make it challenging to draw definitive conclusions and may require additional methods such as subgroup analysis or meta-regression to try and identify and explore potential reasons for the variation in effect sizes between studies. Furthermore, since the sum of patients was small for some of the studied risk factors found in these studies, conclusions should be interpreted with caution.

Nevertheless, the guideline's validation may be performed using simulation tests and, thus, it has the potential to become a great clinical instrument in the future. We also argue that the high heterogeneity in current literature emphasizes the need for a standardized and consensual method for diagnosing and reporting PAS.

CONCLUSION

Safe and effective care of a woman with a PAS disorder depends on a timely diagnosis. An efficient and organized screening program for PAS is crucial in referring medical settings, as it would enable early detection and referral of high-risk women to PAS diagnostic centers. A high level of suspicion is necessary for early diagnosis and, in this, profiling the women with known relevant risk factors is essential.

Our results directly impact the ability of screening – with the proposed guideline, we can identify the women that will benefit from an early referral to experts, which may increase the rate of antenatal diagnosis and reduce PAS-related complications with proper planning and follow-up.

REFERENCES

1. Jauniaux E, Ayres-de-Campos D, Duncombe G, Klaritsch P, Chantraine F, Kingdom J, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: Introduction. *International Journal of Gynecology and Obstetrics*. 2018;140(3):261-4.
2. Morlando M, Collins S. Placenta accreta spectrum disorders: Challenges, risks, and management strategies. *Int J Womens Health*. 2020;12:1033-45.
3. Goulding AN, Casey S, Reed CC, Shamshirsaz AA, Lombaard H, Belfort MA, et al. Perinatal mental healthcare utilization among patients with placenta accreta spectrum. *Am J Obstet Gynecol [Internet]*. 2023;228(1):S257. Available from: <https://doi.org/10.1016/j.ajog.2022.11.465>
4. O'Brien JM, Barton JR, Donaldson ES. The management of placenta percreta: Conservative and operative strategies. *Am J Obstet Gynecol*. 1996;175(6):1632-8.
5. Thang NM, Anh NTH, Thanh PH, Linh PT, Cuong TD. Emergent versus planned delivery in patients with placenta accreta spectrum disorders: A retrospective study. *Medicine (United States)*. 2021;100(51):E28353.
6. Zhong W, Zhu F, Li S, Chen J, He F, Xin J, et al. Maternal and Neonatal Outcomes After Planned or Emergency Delivery for Placenta Accreta Spectrum: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)*. 2021;8(September).
7. Schwicker A, van Beekhuizen HJ, Bertholdt C, Fox KA, Kayem G, Morel O, et al. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): A multinational database study. *Acta Obstet Gynecol Scand*. 2021;100(S1):29-40.
8. Badr DA, Al Hassan J, Salem Wehbe G, Ramadan MK. Uterine body placenta accreta spectrum: A detailed literature review. *Placenta [Internet]*. 2020;95(April):44-52. Available from: <https://doi.org/10.1016/j.placenta.2020.04.005>
9. Cali G, Labate F, Cucinella G, Fabio M, Buca D, Di Girolamo R, et al. Placenta accreta spectrum disorders in twin pregnancies as an under reported clinical entity: a case series and systematic review. *Journal of Maternal-Fetal and Neonatal Medicine [Internet]*. 2022;35(25):8848-51. Available from: <https://doi.org/10.1080/14767058.2021.2005568>
10. Mittal P, Suri J, Pruthi N, Pandey D, Bharti R. Comparison of placenta accreta spectrum disorders diagnosed in intrapartum and antepartum period – A three year experience in a tertiary referral unit of India. *European Journal of Obstetrics and Gynecology and Reproductive Biology*. 2019 May 1;236:41-5.
11. Svanvik T, Jacobsson AK, Carlsson Y. Prenatal detection of placenta previa and placenta accreta spectrum: Evaluation of the routine mid-pregnancy obstetric ultrasound screening between 2013 and 2017. *International Journal of Gynecology and Obstetrics*. 2022 Jun 1;157(3):647-53.
12. Coutinho CM, Giorgione V, Noel L, Liu B, Chandraran E, Pryce J, et al. Effectiveness of contingent screening for placenta accreta spectrum disorders based on persistent low-lying placenta and previous uterine surgery. *Ultrasound in Obstetrics and Gynecology*. 2021 Jan 1;57(1):91-6.
13. Zheng J, Liu S, Xing J. Prognosis and related risk factors of

patients with scarred uterus complicated with central placenta previa. *Ginekol Pol.* 2019;90(4):185-8.

14. Kayem G, Seco A, Beucher G, Dupont C, Branger B, Crenn Hebert C, et al. Clinical profiles of placenta accreta spectrum: the PACCRETA population-based study. *BJOG.* 2021;128(10):1646-55.

15. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J, Duncombe G, Klaritsch P, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. *International Journal of Gynecology and Obstetrics.* 2018;140(3):265-73.

16. Conturie CL, Lyell DJ. Prenatal diagnosis of placenta accreta spectrum. *Curr Opin Obstet Gynecol.* 2022;34(2):90-9.

17. Ornaghi S, Maraschini A, Donati S, Donati S, Maraschini A, D'Aloja P, et al. Characteristics and outcomes of pregnant women with placenta accreta spectrum in Italy: A prospective population-based cohort study. Vol. 16, *PLoS ONE. Public Library of Science;* 2021.

18. WHO recommendations non-clinical interventions to reduce unnecessary caesarean sections.

19. Vestal NL, Mandelbaum RS, Matsuzaki S, Sangara RN, Bainvoll L, Ouzounian JG, et al. Assisted Reproductive Technology and Increased Abnormal Placentation: a Population-Based Analysis. *Fertil Steril [Internet].* 2021;116(3):e230. Available from: <https://doi.org/10.1016/j.fertnstert.2021.07.623>

20. De Mucio B, Serruya S, Alemán A, Castellano G, Sosa CG. A systematic review and meta-analysis of cesarean delivery and other uterine surgery as risk factors for placenta accreta. Vol. 147, *International Journal of Gynecology and Obstetrics. John Wiley and Sons Ltd.;* 2019. p. 281-91.

21. Kyoizuka H, Yamaguchi A, Suzuki D, Fujimori K, Hosoya M, Yasumura S, et al. Risk factors for placenta accreta spectrum: Findings from the Japan environment and Children's study. *BMC Pregnancy Childbirth.* 2019 Nov 27;19(1).

22. Matsuzaki S, Mandelbaum RS, Sangara RN, McCarthy LE, Vestal NL, Klar M, et al. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States. *Am J Obstet Gynecol.* 2021 Nov 1;225(5):534.e1-534.e38.

23. Hou YP, Lommel L, Wiley J, Zhou XH, Yao M, Liu S, et al. Influencing factors for placenta accreta in recent 5 years: a systematic review and meta-analysis. *Journal of Maternal-Fetal and Neonatal Medicine [Internet].* 2022;35(11):2166-73. Available from: <https://doi.org/10.1080/14767058.2020.1779215>

24. Ali H, Chandrharan E. Etiopathogenesis and risk factors for placental accreta spectrum disorders. Vol. 72, *Best Practice and Research: Clinical Obstetrics and Gynaecology. Bailliere Tindall Ltd;* 2021. p. 4-12.

25. El Gelany S, Mosbeh MH, Ibrahim EM, Mohammed M, Khalifa EM, Abdelhakium AK, et al. Placenta Accreta Spectrum (PAS) di-

sorders: Incidence, risk factors and outcomes of different management strategies in a tertiary referral hospital in Minia, Egypt: A prospective study. *BMC Pregnancy Childbirth.* 2019;19(1):1-8.

26. Ogawa K, Jwa SC, Morisaki N, Sago H. Risk factors and clinical outcomes for placenta accreta spectrum with or without placenta previa. *Arch Gynecol Obstet.* 2022 Mar 1;305(3):607-15.

27. Guo Z, Han X, Zheng W, Yang H, Ma J. Placenta Accreta Spectrum Among Multiple Gestation: A Retrospective Analysis Based on a Chinese Population. *Front Endocrinol (Lausanne).* 2022;13(May):1-7.

28. Jenabi E, Salimi Z, Salehi AM, Khazaei S. The environmental risk factors prior to conception associated with placenta accreta spectrum: An umbrella review. Vol. 51, *Journal of Gynecology Obstetrics and Human Reproduction. Elsevier Masson s.r.l.;* 2022.

29. Jauniaux E, Bhide A, Kennedy A, Woodward P, Hubinont C, Collins S, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. *International Journal of Gynecology and Obstetrics.* 2018;140(3):274-80.

30. Mullen CR, Battarbee AN, Ernst LM, Peaceman AM. Focal Placenta Accreta: Risk Factors, Adverse Obstetrical Outcomes, and Recurrence in Subsequent Pregnancies [10L]. *Obstetrics & Gynecology [Internet].* 2017;129(5). Available from: https://journals.lww.com/greenjournal/Fulltext/2017/05001/Focal_Placenta_Accreta_Risk_Factors,_Adverse.444.aspx

31. Erfani H, Salmanian B, Aagaard KM, Fox KA, Meshinchiasl N, Shamshirsaz AA, et al. 1131 Microscopic placenta accreta as a risk factor for placenta accreta spectrum in a subsequent pregnancy. *Am J Obstet Gynecol [Internet].* 2021;224(2):S697-8. Available from: <http://dx.doi.org/10.1016/j.ajog.2020.12.1155>

AUTHORS' CONTRIBUTIONS

Anaísa S. Simões: conceptualization, data curation, methodology, writing – original draft, review and editing; Isabel Santos Silva: conceptualization, data curation, supervision, writing – review and editing; Francisco Caramelo – formal statistical analysis and validation, supervision, writing – review and editing.

CONFLICT OF INTEREST

The authors declare to have no conflict of interest.

CORRESPONDENCE TO:

Anaísa S. Simões

E-mail: anaisa.s.simoes@gmail.com

<https://orcid.org/0009-0009-1966-0918>

RECEIVED: 19/02/2024

ACCEPTED: 12/06/2024